ClinicalTrials.gg
CompletedNCT03236857Updated May 22, 2023

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

A Phase 1 interventional study of chemotherapy and venetoclax in Malignancies, Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML), sponsored by AbbVie. Completed at 31 sites in 8 countries. Open to participants aged 0 Years to 25 Years. Per ClinicalTrials.gov, last updated 2023-05-22.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
143
Allocation
Not applicable
Ages
0 Years to 25 Years
Sex
All
01

Study summary

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

02

Conditions studied

  • Malignancies
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Non-Hodgkin's Lymphoma
  • Neuroblastoma

Keywords

  • Cancer
  • Venetoclax
  • pediatric
  • relapsed or refractory
  • Venclexta
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 143 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have cancer.
  • Participants must have adequate hepatic and kidney function.
  • Participants less than or equal to 16 years of age must have performance status of Lansky greater than or equal to 50% and participants greater than 16 years of age must have performance status of greater than or equal to 50%.
  • Participants with solid tumors (with the exception of neuroblastoma) must have adequate bone marrow function in Part 1.
  • For the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors must have evidence of BCL-2 expression (except participants with TCF3-HLF ALL).

Exclusion criteria

Exclusion Criteria:

  • Participants with primary brain tumors or disease to the brain.
  • Participants who have central nervous system (CNS) disease with cranial involvement that requires radiation.
  • Participants who have received any of the following within the listed time frame, prior to the first dose of study drug

    • Inotuzumab ozogamicin or gemtuzumab ozogamicin within 30 days
    • Biologic agent (i.e., antibodies) for anti-neoplastic intent within 30 days or 5 half-lives whichever is shorter.
    • CAR-T infusion or other cellular therapy within 30 days
    • Anticancer therapy including chemotherapy, radiation therapy, targeted small molecule agents, agents within 14 days or 5 half-lives, whichever is shorter (Exceptions: Ph+ALL participants on Tyrosine Kinase Inhibitor (TKI) at Screening may enroll and remain on TKI therapy to control disease and TCF3-HLF ALL participants are allowed to have received chemotherapy within 14 days or 5 half-lives, whichever is shorter).
    • therapy for anti-neoplastic intent within 5 days (with the exception of TCF3-HLF ALL participants).
    • Requires ongoing hydroxyurea (hydroxyurea permitted up to first dose)
  • Participants who are less than 100 days post-transplant, or greater than or equal to 100 days post-transplant with active (GVHD), or are receiving therapy within 7 days prior to first dose of study drug.
  • Participants who are less than 6 weeks post-131 I-metaiodobenzylguanidine (mIBG) therapy.
  • Participants who have received the following within 7 days prior to the first dose of study drug:

    • Strong and moderate Cytochrome P450 3A () inhibitors (Part 1 Dose Determination);
    • Strong and moderate CYP3A inducers (Part 1 Dose Determination and Part 2 Cohort Expansion).
  • Participants who have not recovered from adverse effect(s)/toxicity(s) of the previous therapy (Exception: Chemotherapy induced side effects that are expected to return to baseline in TCF3-HLF ALL participants).
  • Participants who have active, uncontrolled infections.
  • Participants with malabsorption syndrome or any other condition that precludes enteral administration.

    • Participants with recent positive test for SARS-CoV-2 (COVID-19) and no follow up test with negative result cannot be enrolled. Participants with contact to persons with COVID-19 and participants with signs and symptoms for COVID-19 infection must be tested before enrolling.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Venetoclax with or without chemotherapy

    Venetoclax administered orally once daily (QD) with various doses and dosing regimens with or without chemotherapy at the discretion of the investigator. Allowed chemotherapy regimens as outlined in the study protocol.

    Drug: chemotherapy · Drug: venetoclax

Interventions

  • Drugchemotherapy

    Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan

  • Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)

    Also known as: ABT-199, GDC-0199, Venclexta

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to 9 months

  2. Number of Participants With Dose Limiting Toxicities (DLT) of Venetoclax Monotherapy

    A DLT is any Grade 3 or higher non-hematologic adverse event (AE) with exceptions outlined in the protocol.

    Time frame: First 21 days venetoclax monotherapy

  3. Recommended Phase 2 dose (RPTD) of Venetoclax

    Venetoclax RPTD is the dose determined based on adverse event reporting and dose-limiting toxicity information from all participants.

    Time frame: First 21 days venetoclax monotherapy

  4. Cmax of Venetoclax

    Maximum plasma concentration (Cmax) of venetoclax.

    Time frame: Up to approximately 2 weeks

  5. Tmax of venetoclax

    Time to maximum plasma concentration (Tmax) of venetoclax.

    Time frame: Up to approximately 2 weeks

  6. AUC0-24 Post-Dose of Venetoclax

    Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax.

    Time frame: Up to approximately 2 weeks

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who achieved a response according to established criteria described in detail in the study protocol.

    Time frame: Up to 9 months

  2. Partial Response (PR) Rate

    PR is defined according to established criteria for each tumor type and is described in detail within the study protocol.

    Time frame: Up to 9 months

  3. Complete Response (CR) Rate

    CR is defined according to established criteria for each tumor type and is described in detail within the study protocol.

    Time frame: Up to 9 months

07

Study locations

31 sites
  • Univ California, San Francisco /ID# 163460
    San Francisco, California 94143-2204, United States
  • Children's Hospital Colorado /ID# 161551
    Aurora, Colorado 80045, United States
  • Children's Healthcare of Atlan /ID# 161552
    Atlanta, Georgia 30322, United States
  • Dana-Farber Cancer Institute /ID# 163440
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 163444
    New York, New York 10065-6007, United States
  • Cincinnati Children's Hospital /ID# 161550
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia /ID# 163445
    Philadelphia, Pennsylvania 19104, United States
  • St Jude Children's Research Hospital /ID# 163447
    Memphis, Tennessee 38105, United States
  • Primary Children's /ID# 164399
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital /ID# 163459
    Seattle, Washington 98105, United States
  • Medical College of Wisconsin /ID# 163461
    Milwaukee, Wisconsin 53226-3522, United States
  • Sydney Children's Hospital /ID# 163148
    Randwick, New South Wales 2031, Australia
  • Queensland Children's Hospital /ID# 163146
    South Brisbane, Queensland 4101, Australia
  • Women and Childrens Hospital /ID# 163147
    North Adelaide, South Australia 5006, Australia
  • Royal Children's Hospital /ID# 163104
    Parkville, Victoria 3052, Australia
  • Hospital for Sick Children /ID# 163726
    Toronto, Ontario M5G 1X8, Canada
  • CHU Sainte-Justine /ID# 163725
    Montreal, Quebec H3T 1C5, Canada
  • AP-HM - Hopital de la Timone /ID# 161465
    Marseille CEDEX 05, Bouches-du-Rhone 13385, France
  • Centre Leon Berard /ID# 163707
    Lyon CEDEX 08, Rhone 69373, France
  • AP-HP - Hopital Armand-Trousseau /ID# 163728
    Paris, 75012, France
  • Robert Debre Hopital, FR /ID# 161464
    Paris, 75019, France
  • CHU Toulouse - Hôpital des enfants /ID# 163727
    Toulouse CEDEX 9, 31059, France
  • Universitaetsklinikum Freiburg /ID# 164206
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 161729
    Kiel, Schleswig-Holstein 24105, Germany
  • Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 161730
    Berlin, 13353, Germany
  • Universitaetsklinikum Essen /ID# 164207
    Essen, 45147, Germany
  • Erasmus MC - Sophia /ID# 161579
    Rotterdam, 3015 GD, Netherlands
  • Prinses Maxima Centrum /ID# 162670
    Utrecht, 3584 CS, Netherlands
  • Kinderspital Zurich - Eleonorenstiftung /ID# 163037
    Zurich, Zuerich 8032, Switzerland
  • Great Ormond Street Hospital for Children /ID# 169238
    London, London, City Of WC1N 3JH, United Kingdom
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 162938
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
08

References and documents

Publications

  • Dalton KM, Krytska K, Lochmann TL, Sano R, Casey C, D'Aulerio A, Khan QA, Crowther GS, Coon C, Cai J, Jacob S, Kurupi R, Hu B, Dozmorov M, Greninger P, Souers AJ, Benes CH, Mosse YP, Faber AC. Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma. Mol Cancer Ther. 2021 Aug;20(8):1400-1411. doi: 10.1158/1535-7163.MCT-20-0710. Epub 2021 Jun 4. PubMed 34088831 ↗
  • Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J. Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29. PubMed 29595064 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Apr 2023, 65 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 65 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2017
First posted
Aug 2, 2017
StartActual
Nov 8, 2017
Primary completionActual
Apr 19, 2023
CompletionActual
Apr 19, 2023
Last update
May 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03236857
Lead sponsor
AbbVie
Collaborators
Roche-Genentech
Responsible party
Sponsor
First posted
Aug 2, 2017
Start date
Nov 8, 2017
Primary completion
Apr 19, 2023
Completion
Apr 19, 2023
Last update
May 22, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion